Table 1 Demographic and clinical features of the 82 patients who completed the 12-week follow-up
Variables | Number (%) or mean±SD | p-value | ||
|---|---|---|---|---|
| Â | All | HFEM | CM | |
Patients | 82 | 35 | 47 | Â |
Age, yrs | 45.3±14.7 | 47.1±13.3 | 44.1±15.6 | 0.366 |
Females | 75 (91.5) | 29 (82.9) | 46 (97.9) | 0.040 |
BMI | 23.4±3.8 | 23.2±3.2 | 23.4±3.5 | 0.866 |
Age at onset, yrs | 15.1±6.4 | 16.0±6.0 | 14.4±6.7 | 0.276 |
MMD | 10.2±2.7 | 10.2±2.7 | - | - |
MHD | 22.7±5.6 | - | 22.7±5.6 | - |
NRS | 8.0±1.0 | 8.1±1.0 | 8.0±1.0 | 0.892 |
Medication overuse | 34 (41.5) | - | 34 (72.3) | - |
Medication overuse duration, yrs | 5.5±5.4 | - | 5.5±5.4 | - |
Unilateral pain | 11 (13.4) | 4 (11.4) | 7 (14.9) | 0.649 |
UAS | 29 (35.4) | 8 (22.9) | 21 (44.7) | 0.041 |
CAPS | 1.1±1.9 | 0.6±1.3 | 1.5±2.2 | 0.029 |
Allodynia | 14 (17.1) | 4 (11.4) | 10 (21.3) | 0.241 |
ASC-12 | 2.3±3.8 | 1.5±3.3 | 2.9±4.0 | 0.034 |
Dopaminergic symptoms | 24 (29.3) | 4 (11.4) | 20 (42.6) | 0.002 |
MAI | 18.5±10.6 | 11.1±5.9 | 23.2±10.2 | <0.001 |
Pts using concomitant prophylaxis | 27 (33.0) | 8 (22.9) | 19 (40.4) | 0.094 |
Prior treatment failures | 4.4±2.4 | 3.5±2.0 | 5.0±2.9 | 0.050 |
Pts with prior treatment failures with anti-CGRP mAbs | 34 (41.5) | 9 (25.7) | 25 (53.2) | 0.012 |
Pts with prior treatment failure to OnabotulinumtoxinA | 11 (13.4) | 1 (2.9) | 10 (21.3) | 0.155 |
Pts with >1 comorbidity | 48 (58.5) | 20 (57.1) | 28 (59.6) | 0.825 |
Pts with psychiatric comorbidities | 27 (32.9) | 10 (28.6) | 17 (36.2) | 0.469 |
HIT-6 | 64.4±9.5 | 61.7±11.4 | 66.4±7.0 | 0.094 |
MIDAS | 84.5±76.0 | 65.9±68.8 | 97.3±78.8 | 0.004 |
MIBS-4 | 9.2±3.4 | 9.0±3.2 | 9.3±3.6 | 0.553 |